Home - Products - Chromatin/Epigenetic - Epigenetic Reader Domain - SMARCA-BD ligand 1 for Protac dihydrochloride

SMARCA-BD ligand 1 for Protac dihydrochloride

CAS No. 2369053-68-7

SMARCA-BD ligand 1 for Protac dihydrochloride( —— )

Catalog No. M33234 CAS No. 2369053-68-7

SMARCA-BD ligand 1 for Protac dihydrochloride binds to the BAF ATPase subunit SMARCA2 and is used for degrading SMARCA2 based on PROTAC.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 93 Get Quote
5MG 140 Get Quote
10MG 227 Get Quote
25MG 364 Get Quote
50MG 523 Get Quote
100MG 700 Get Quote
500MG 1413 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SMARCA-BD ligand 1 for Protac dihydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    SMARCA-BD ligand 1 for Protac dihydrochloride binds to the BAF ATPase subunit SMARCA2 and is used for degrading SMARCA2 based on PROTAC.
  • Description
    SMARCA-BD ligand 1 for Protac dihydrochloride is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2369053-68-7
  • Formula Weight
    344.24
  • Molecular Formula
    C14H19Cl2N5O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 2.7 mg/mL (7.84 mM; Ultrasonic (<60°C)
  • SMILES
    Cl.Cl.Nc1nnc(cc1N1CCNCC1)-c1ccccc1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Farnaby W, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019 Jul;15(7):672-680.?
molnova catalog
related products
  • SRX3177

    SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.

  • BAZ1A-IN-1

    BAZ1A-IN-1 is a potent BAZ1A inhibitor with the KD value of 0.52 μM for the BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-survival activity against cancer cell lines with high BAZ1A expression, but weak or no activity against cancer cells with low BAZ1A expression.

  • Y06137

    Y06137 is an effective and selective BET inhibitor with a Kd of 81 nM for BRD4(1) bromodomain. Y06137 can be used for research on the treatment of castration-resistant prostate cancer.